Education
About Us
Working with TipRanks
Follow Us
Steven Brian Gieni Insider Profile
4 Followers
Steven Brian Gieni, Former at Claritas Pharmaceuticals, holds 178.50K shares in Claritas Pharmaceuticals (Ticker: CLAZF). Most recently, Steven Brian Gieni Bought 178,500 shares of Claritas Pharmaceuticals on Mar 26, 2010 for an estimated value of $24.99K.
Steven Brian Gieni has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Holdings
Steven Brian Gieni does not currently own shares as a corporate insider.
A breakdown of Steven Brian Gieni's holdings
Insider Roles
Former
Roles that Steven Brian Gieni holds in companies
Most Profitable Insider Trade
Currently, no data available
The most profitable trade made by Steven Brian Gieni
Steven Brian Gieni's Trading History
List of latest transactions for each holding click on a transaction to see Steven Brian Gieni's performance on stock
You May Also Like
Steven Brian Gieni insider profile FAQ
What is the percentage of profitable transactions made by Steven Brian Gieni?
The percentage of profitable transactions made by Steven Brian Gieni is ―.
What is the average return per transaction made by Steven Brian Gieni?
The average return per transaction made by Steven Brian Gieni is ―.
What stocks does Steven Brian Gieni hold?
Steven Brian Gieni holds: CLAZF stocks.
What was Steven Brian Gieni’s latest transaction?
Steven Brian Gieni latest transaction was an Informative Buy of $24.99K.
What was Steven Brian Gieni's most profitable transaction?
Steven Brian Gieni’s most profitable transaction was an Uninformative Buy of stock on ―. The return on the trade was ―.
What is Steven Brian Gieni's role in Claritas Pharmaceuticals?
Steven Brian Gieni's role in Claritas Pharmaceuticals is Former.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.